A pilot study of trimodality breast imaging surveillance in young women at high risk of breast cancer in Western Australia

Christobel M Saunders, Gudrun Peters, Glenys Longman, Jacqueline Thomson, Donna Taylor, Jianmin Hua, Michelle Bennett, Elizabeth Wylie, Jack Goldblatt, Arlene Chan and James Anderson

Breast cancer is the most common cause of cancer-related death in Australian women, with the Australian Institute of Health and Welfare reporting 2641 deaths from the disease in 2004 and predicting 14800 new cases in 2011. Population mammographic screening programs using age as the principal risk criterion have been in place in Australia since 1992. The main target population of such programs is women aged 50–69 years. In younger women at high risk of developing breast cancer, the value of mammography is limited by a higher prevalence of dense breast tissue, with low sensitivity of this imaging modality and concerns over radiation exposure.

Although up to 15% of breast cancers may have a familial component, it is estimated that about 5% arise from mutations in the high-risk cancer susceptibility genes BRCA1 and BRCA2. Women at high risk were advised in the National Breast and Ovarian Cancer Centre recommendations to have annual surveillance with a mammographic x-ray (MMX), with or without a breast ultrasound (U/S) scan and clinical breast examination (CBE), and were advised to practise breast self-examination.

The Medical Services Advisory Committee of the Australian Government Department of Health and Ageing has recently provided interim public funding for the use of magnetic resonance imaging (MRI) to screen for breast cancer in asymptomatic women under 50 years of age with a high risk of developing breast cancer. Medicare benefits have been available for the procedure since 1 February 2009 (item numbers 63464 and 63467).

**ABSTRACT**

**Objective:** To determine whether a surveillance program including clinical breast examination (CBE) and three screening modalities (magnetic resonance imaging [MRI], high-resolution ultrasound [U/S] and mammographic x-ray [MMX]) was feasible, and whether it could improve detection of pathological lesions in young women at high risk of developing breast cancer.

**Design, setting and participants:** Western Australian women aged 50 years or under at high risk of developing breast cancer were recruited to our study. For a 2-year period, they were offered breast MRI and U/S scans in addition to their annual MMX and CBE. Our study was conducted between June 2002 and October 2005.

**Main outcome measures:** Number and type of cancerous or precancerous lesions; recall rates after screening; comparative sensitivity of screening modalities.

**Results:** Of 102 women approached, 72 agreed to participate. Fifteen lesions were detected, of which three were significant: a metastatic papilliferous cancer in an axillary lymph node, a borderline lesion (multiple papillomatosis with atypia), and a papilloma. All 15 lesions were visible on MRI, and four were detected by MRI only. Only one lesion was visible on all three imaging modalities. Nothing significant was detected by CBE. The recall rate after MRI scans fell from 9/72 (12.5%) in the first year to 5/67 (7.5%) in the second year.

**Conclusion:** Our study gave valuable experience in a team approach to screening MRI, and showed that MRI can detect more lesions than MMX or U/S in women at high risk of developing breast cancer. Screening U/S may not add value to MMX and MRI screening, and we suggest a single oblique-view MMX may be used in some cases.

The aim of our study was to determine whether a surveillance program involving CBE and three screening modalities (MRI, U/S and MMX) was feasible, and whether it could improve detection of pathological lesions in young women at high risk. Before our study, MRI was not routinely used anywhere in Australia for screening women at high risk of breast cancer.

**METHODS**

**Study population**

The participants in our study were Western Australian women recruited from the Royal Perth Hospital’s multidisciplinary high-risk surveillance clinic. All eligible women attending over the study period were approached. Entry for our study was based on Australian risk category 3 criteria for women at potentially high risk of breast cancer due to their family history, including those with known gene mutations. Women at high risk due to previously diagnosed breast conditions (such as atypical ductal hyperplasia or ductal carcinoma-in-situ) were also recruited. All women were aged 50 years or under at study entry. Pregnant or lactating women and women with a personal history of invasive breast cancer were excluded.

**Study protocol**

Our study was performed between June 2002 and October 2005. Surveillance involved a CBE every 6 months and trimodality imaging (MMX, high-resolution U/S and dynamic MRI) performed once a year for 2 years. All imaging was done at the Royal Perth Hospital and Perth Radiological Clinic. Breast MRI examinations in premenopausal women were done between Day 6 and Day 16 of the menstrual cycle.

**Biopsies**

A biopsy was performed if a lesion detected by any modality was classified as imaging category 3 or higher according to the image.

<table>
<thead>
<tr>
<th>Abbreviations</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BI-RADS</td>
<td>Breast Imaging Reporting and Data System</td>
</tr>
<tr>
<td>CBE</td>
<td>Clinical breast examination</td>
</tr>
<tr>
<td>MMX</td>
<td>Mammographic x-ray</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>U/S</td>
<td>Ultrasound</td>
</tr>
</tbody>
</table>

MJA 2009; 191: 330–333
classification system of the American College of Radiology — the Breast Imaging Reporting and Data System (BI-RADS). This included MMX- or U/S-guided biopsies. If the lesion was visible on MRI but not on targeted U/S, short-term follow-up (at 3–6 months) was recommended. No lesions that were seen on MRI only were considered sufficiently suspicious to warrant surgical removal.

Follow-up
Patients were followed up according to the schema shown in Box 1.

Ethics approval
Our study was approved by the Royal Perth Hospital Human Research Ethics Committee. Informed consent was obtained from all participants.

RESULTS
Of 102 women who were approached, 72 consented to participate. Many who declined did so because they were, or wished to become, pregnant and wanted to avoid imaging. Others declined because their place of residence was too far from the study centre or they were highly mobile in their lifestyle.

The age groups of the 72 women and their breast density categories (assessed by BI-RADS criteria) are summarised in Box 2.

Among the 72 women over the 2-year period, one metastatic papillary cancer in an axillary lymph node, one borderline lesion (multiple papillomatosis with atypia) and one solid atypical lesion (papilloma) were identified. No primary invasive breast cancers were detected during the study period. (However, two cancers were detected subsequently.)

Sixty-seven women were categorised as being at high risk of breast cancer based on their family history. Of these, 12 were known carriers of gene mutations (seven with BRCA1 and five with BRCA2 mutations). The remaining five women had biopsy-proven high-risk conditions (ductal carcinoma-in-situ [1], atypical ductal hyperplasia [2], papillomatosis [1] and encysted papillary carcinoma [1]).

The patient with metastatic papillary cancer in an axillary lymph node was in the biopsy-proven high-risk condition group (she had previously had a resection of an encysted papillary carcinoma); the patient with a borderline lesion was a BRCA1 mutation carrier; and the patient with the papilloma was in the high-risk category (having a mother, two sisters and a maternal first cousin with breast cancer), but BRCA gene

<table>
<thead>
<tr>
<th>Patient age (years)</th>
<th>Visible on MMX</th>
<th>Visible on U/S</th>
<th>Number of lesions</th>
<th>Investigation/intervention</th>
<th>Histological diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>No</td>
<td>No</td>
<td>1</td>
<td>Surgical removal</td>
<td>Metastatic papillary cancer in axillary lymph node</td>
</tr>
<tr>
<td>32</td>
<td>Yes</td>
<td>No</td>
<td>1</td>
<td>MMX-guided biopsy†</td>
<td>Benign breast changes</td>
</tr>
<tr>
<td>35</td>
<td>No</td>
<td>No</td>
<td>1</td>
<td>6-month MRI follow-up:</td>
<td>(No biopsy)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>no change</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>No</td>
<td>Yes</td>
<td>1</td>
<td>Targ U/S and U/S-GB†</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>34</td>
<td>No</td>
<td>No</td>
<td>1</td>
<td>6-month MRI follow-up:</td>
<td>(No biopsy)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>no change</td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>Yes</td>
<td>Yes</td>
<td>2</td>
<td>Surgical removal</td>
<td>Papillomatosis, fibroadenoma</td>
</tr>
<tr>
<td>37</td>
<td>Yes</td>
<td>Yes</td>
<td>1</td>
<td>Targ U/S and U/S-GB†</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>44</td>
<td>No</td>
<td>Yes</td>
<td>1</td>
<td>Targ U/S and U/S-GB†</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>29</td>
<td>No</td>
<td>Yes</td>
<td>1</td>
<td>Targ U/S and U/S-GB†</td>
<td>Fibroadenoma</td>
</tr>
</tbody>
</table>

MMX = mammographic x-ray. MRI = magnetic resonance imaging. Targ = targeted. U/S = ultrasound. U/S-GB = ultrasound-guided biopsy. *All lesions were visible on MRI. †Core or vacuum biopsy.
Recall rates and comparison of screening modalities

Over the study period, 139 screening MRI scans were performed. Five women did not return for their second scan (three declined because of difficulty attending, one moved interstate, and one became pregnant).

The recall rate after MRI scans was 10.1% overall (Box 3, Box 4), declining from 9/72 cases (12.5%) in the first year to 5/67 cases (7.5%) in the second year.

The 15 lesions that resulted in the 14 recalls (one patient had two lesions) were all visible on MRI. Four lesions were visible on MRI only, and one was visible on all three imaging modalities. Of the remaining lesions, two were seen on MMX but not U/S, and eight were seen on U/S but not MMX.

No microcalcifications were visible on MMX, and nothing of significance was detected by CBE.

**DISCUSSION**

Numerous studies have demonstrated the value of MRI as part of imaging surveillance for women at high risk of developing breast cancer.8–13 Our study showed that MRI can be incorporated into a routine surveillance program for such women.

We identified two patients with lesions potentially putting them at higher risk of breast cancer and one with metastatic cancer in an axillary lymph node. The lymph node metastasis was not initially identified in the MRI scan: the patient palpated the node herself 1 month after imaging was done, and when the MRI scan was viewed retrospectively, the metastasis was in fact visible (Box 5). The patient’s imaging occurred early in the study, and failure to detect the cancer was the result of inexperience in interpreting breast MRI scans at that stage. This underscores the importance of carrying out breast MRI examination and reporting in centres that have expert multidisciplinary experience in breast surveillance, including MRI.

The BI-RADS classification system7 advises that lesions classified as category 3 on MRI should be managed by follow-up imaging. We chose to take biopsy samples of category 3 lesions because of the limited understanding of their histological correlates and the uncertain clinical significance of these lesions in women at high risk of breast cancer.

**4 Characteristics of lesions in five patients who were recalled after the second round of MRI scans**

<table>
<thead>
<tr>
<th>Patient age (years)</th>
<th>Visible on MMX</th>
<th>Visible on U/S</th>
<th>Number of lesions</th>
<th>Investigation/intervention</th>
<th>Histological diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>49</td>
<td>No</td>
<td>No</td>
<td>1</td>
<td>6-month MRI follow-up: no change</td>
<td>(No biopsy)</td>
</tr>
<tr>
<td>35</td>
<td>No</td>
<td>Yes</td>
<td>1</td>
<td>Targ U/S and U/S-GB†</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>25</td>
<td>No</td>
<td>Yes</td>
<td>1</td>
<td>Targ U/S and U/S-GB†</td>
<td>Benign papilloma</td>
</tr>
<tr>
<td>50</td>
<td>No</td>
<td>Yes</td>
<td>1</td>
<td>12-month MRI follow-up: no change</td>
<td>(No biopsy)</td>
</tr>
<tr>
<td>28</td>
<td>No</td>
<td>Yes</td>
<td>1</td>
<td>Targ U/S and U/S-GB†</td>
<td>Fibroadenoma</td>
</tr>
</tbody>
</table>

MMX = mammographic x-ray. MRI = magnetic resonance imaging. Targ = targeted. U/S = ultrasound. U/S-GB = ultrasound-guided biopsy. *All lesions were visible on MRI. †Core or vacuum biopsy.

**5 Metastatic papillary cancer in an axillary lymph node (arrow)**

*Identified retrospectively on magnetic resonance imaging scan.

The lower recall rate following the second round of imaging (ie, in the second year of our study) can be explained by the experience gained from investigating the lesions identified in the first round, and also the availability of baseline imaging for comparison. MRI of the breast is reported to have high sensitivity but lower specificity.14 In our study, 15 lesions were detected by MRI (one of them retrospectively), but of these, 12 were false positive cases and one was a false negative. MMX and screening U/S detected fewer lesions than MRI, with only three of the 15 lesions visible on each. However, the use of targeted U/S to locate lesions seen initially only on MRI successfully identified a further six of the 15 lesions. This poses the question as to whether it is more efficient to use targeted U/S (rather than screening U/S) after MRI in patients at high risk. The low sensitivity of mammography in our study can be explained by the young age of the study population (and hence higher breast tissue density).

Given that no microcalcifications were visible on MMX in our study, the question arises as to whether high-quality one-view (lateral oblique view) mammography (rather than two-view mammography) could be used to exclude microcalcifications, thus reducing radiation exposure for young patients at high risk. This may be especially important for women with BRCA1 and BRCA2 mutations that may predispose cells to an increased risk of mutagenesis and transformation after exposure to radiation.15,16

No invasive cancers were found in our study, but two potentially high-risk lesions were detected and malignancy was excluded following excision. Four lesions were detected by MRI only and were not visible on targeted U/S. In a larger group of patients, MRI intervention tools (MR-compatible biopsy devices and MRI-guided hookwire localisations) would be necessary to sample MRI-only detected lesions17,18 and thus reduce unnecessary patient anxiety.
CONCLUSION

We are aware of the descriptive character of our study, and the results presented here are only preliminary. Nevertheless, we achieved our aim of incorporating a new breast imaging modality into surveillance of young women at high risk and gained experience in interpreting breast MRI scans in this setting. Clinicians were able to see both the benefits and challenges of breast MRI.

We would support the careful introduction of breast MRI screening in Australia within a specialist multidisciplinary setting for managing women at high risk of breast cancer. The program should include training of radiological and clinical personnel in these imaging techniques, and a detailed national audit of outcomes, as advocated by the National Working Group on Breast MRI in High Risk Women (and as detailed in the application recently approved by the Medical Services Advisory Committee), with long-term follow-up of outcomes being mandatory. Prospective evaluation of programs will assist in addressing the question of whether MRI screening of women at high risk of developing breast cancer may have an impact on mortality from the disease.

COMPETING INTERESTS

None identified.

AUTHOR DETAILS

Christobel M Saunders, MB BS, FRCS, FRACS, Professor of Surgical Oncology1
Gudrun Peters, FRANZCR, Research Fellow1
Glensys Longman, RN, Research Nurse1
Jacqueline Thomson, MB ChB, FRANZCR, Radiologist1
Donna Taylor, MB BS, FRANZCR, Radiologist3
Jianmin Hua, BSc, Radiation Physicist1
Michelle Bennett, MB ChB, FRANZCR, Radiologist1
Elizabeth Wylie, MB BS, FRANZCR, Clinical Professor,1 and Radiologist3
Jack Goldblatt, MB BS, MD, FRACP, Clinical Geneticist,a and Professor2
Arline Chan, MB BS, FRACP, MMed, Medical Oncologist3
James Anderson, MB BS, FRANZCR, Radiologist2
1 School of Surgery, University of Western Australia, Perth, WA.
2 Perth Radiological Clinic, Perth, WA.
3 Royal Perth Hospital, Perth, WA.
4 King Edward Memorial Hospital, Perth, WA.
5 School of Paediatrics and Child Health, University of Western Australia, Perth, WA.
6 Mount Hospital, Perth, WA.

Correspondence: christobel.saunders@uwa.edu.au

REFERENCES


(Received 4 Jan 2009, accepted 13 May 2009)